Italy’s Alfasigma to purchase Intercept Pharmaceuticals for $794m

By NS Healthcare Staff Writer

27 Sep 23

Intercept is engaged in developing and commercialising novel therapeutics for rare and serious liver diseases, and its acquisition…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development

By NS Healthcare Staff Writer

25 Sep 23

Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

RefleXion licenses 3BP’s RXM-4768 molecule for unmet cancer needs

By NS Healthcare Staff Writer

21 Sep 23

Under the licensing agreement, RefleXion will develop and commercialise RXM-4768 molecule to direct its SCINTIX biology-guided radiotherapy

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

BioNTech, CEPI partner to boost mRNA-based mpox vaccine development

By NS Healthcare Staff Writer

19 Sep 23

CEPI will contribute up to $90m funding for the partnership, which will support the development of mRNA-based vaccine…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

ROME raises $72m in Series B extension for lead programme development

By NS Healthcare Staff Writer

13 Sep 23

The money raised from the Series B extension will be used by ROME to advance its LINE-1 reverse…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Pierre Fabre acquires Swiss biotechnology company Vertical Bio

By NS Healthcare Staff Writer

13 Sep 23

Through the acquisition, the French firm adds VERT-002, a monoclonal antibody that targets and degrades c-MET, which is…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

China’s Grit Biotechnology raises $60m in Series B to develop TIL portfolio

By NS Healthcare Staff Writer

11 Sep 23

The financing is expected to drive Grit Biotechnology’s Phase 2 trial for GT101 and further development of next-generation…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Kriya buys Tramontane Therapeutics and FGF21 assets portfolio for NASH

By NS Healthcare Staff Writer

07 Sep 23

With the transaction, Kriya now own Tramontane’s FGF21 assets, including the latter’s adeno-associated virus (AAV) vector programme, designed…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Viatris gets tentative approval from US FDA for paediatric HIV formulation

By NS Healthcare Staff Writer

06 Sep 23

Abacavir/dolutegravir/lamivudine is a fixed-dose combination that consists of a pair of nucleoside reverse transcriptase inhibitors (NRTIs) and integrase…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Amgen and Horizon resolve FTC lawsuit to close proposed $27.8bn acquisition

By NS Healthcare Staff Writer

04 Sep 23

The consent order agreement with FTC allows Amgen to complete its proposed $27.8bn acquisition of Horizon Therapeutics, while…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates